Quote Overview

Stock Activity

Open	335.19
Day Low	334.44
Day High	338.51
52 Wk Low	249.98
52 Wk High	361.41
Avg. Volume	1,108,426
Market Cap	128.28 B
Dividend	3.20 ( 0.95%)
Beta	0.89

Key Earnings Data

Earnings ESP	-0.78%
Most Accurate Est	2.33
Current Qtr Est	2.35
Current Yr Est	11.86
Exp Earnings Date	^*AMC4/30/24
Prior Year EPS	10.60
Exp EPS Growth (3-5yr) 10.47%
Forward PE	28.42
PEG Ratio	2.71

Medical » Medical - Products

*BMO = Before Market Open *AMC = After Market Close

Research Reports for SYK

All Zacks’ Analyst Reports

Premium Research for SYK

Style Scores C Value C Growth B Momentum C VGM
Zacks Rank	Hold 3
Zacks Industry Rank	Bottom 44%(140 out of 252)
Zacks Sector Rank	Top 25% (4 out of 16)
Earnings ESP	-0.78%
Research Reports for SYK Analyst \| Snapshot

( = Change in last 30 days)

View All Zacks Rank #1 Strong Buys

Premium Research: Industry Analysis

Top Peers	Symbol	Zacks Rank
Stryker	SYK
High Tide	HITI
ICU Medical	ICUI
LeMaitre Vascular	LMAT
AdaptHealth	AHCO
Aurora Cannabis	ACB
Ayr Wellness Inc.	AYRWF

See all Medical - Products Peers

Zacks News for SYK

No Record found.

Company Summary

Headquartered in Kalamazoo, MI, Stryker Corporation is one of the world’s largest medical device companies operating in the global orthopedic market. The company has three business segments: Orthopaedics, MedSurg, and Neurotechnology & Spine.

Orthopaedic products primarily include implants used in hip and knee joint replacements and trauma and extremities surgeries.

MedSurg products consists of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical); and reprocessed and remanufactured medical devices (Sustainability) as well as other medical device products used in a variety of medical specialties.

Neurotechnology & Spine division includes both neurosurgical and neurovascular devices. These includes products used for minimally invasive endovascular techniques; traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke.

Spinal implant product offering includes cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies.

It is important to note here that effective from Dec 31, 2021, Stryker has updated its reportable business segments to align to its new internal reporting structure.

2023 at a Glance

Stryker’s full-year revenues totaled $20.5 billion, up 11.1% from the previous year. Adjusted earnings per share of $10.60 increased 13.5% from the previous year.